Australia's most trusted
source of pharma news
Thursday, 22 January 2026
Posted 19 January 2026 AM
Johnson & Johnson has been named the most valuable brand in pharma for the seventh year in a row, with Eli Lilly moving up three spots to number two, and Roche slipping to third.
The rankings were calculated by brand valuation consultancy Brand Finance, and published in the Brand Finance Healthcare 2025 report last year. The figures represent the net economic benefit that a brand owner would achieve by licensing their brand in the open market.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.